492 related articles for article (PubMed ID: 19843487)
1. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
[TBL] [Abstract][Full Text] [Related]
2. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.
Hsiao SH; Chou CH; Lin WL; Lee EJ; Liao LH; Chang HJ; Yeh PY; Lin CY; Wu TJ
J Clin Pharm Ther; 2012 Jun; 37(3):296-300. PubMed ID: 22017186
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy.
Pai MP; Mercier RC; Koster SA
Ann Pharmacother; 2006 Feb; 40(2):224-8. PubMed ID: 16434560
[TBL] [Abstract][Full Text] [Related]
4. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
[TBL] [Abstract][Full Text] [Related]
5. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
6. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
7. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.
Hsiao SH; Chen HH; Chou CH; Lin WL; Liu Yeh PY; Wu TJ
J Clin Pharm Ther; 2010 Dec; 35(6):729-32. PubMed ID: 21054466
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin-induced neutropenia resolves after substitution with teicoplanin.
Sanche SE; Dust WN; Shevchuk YM
Clin Infect Dis; 2000 Sep; 31(3):824-5. PubMed ID: 11017842
[TBL] [Abstract][Full Text] [Related]
9. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
[TBL] [Abstract][Full Text] [Related]
10. Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin.
Hsiao SH; Chang CM; Tsai JC; Lin CY; Liao LH; Lin WL; Wu TJ
Ann Pharmacother; 2007 May; 41(5):891-4. PubMed ID: 17426073
[TBL] [Abstract][Full Text] [Related]
11. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
Raad I; Darouiche R; Vazquez J; Lentnek A; Hachem R; Hanna H; Goldstein B; Henkel T; Seltzer E
Clin Infect Dis; 2005 Feb; 40(3):374-80. PubMed ID: 15668859
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
14. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial.
Pico JL; Marie JP; Chiche D; Guiguet M; Andremont A; Lapierre V; Richet H; Tancrede C; Lagrange P; Hayat M
Eur J Med; 1993 May; 2(5):275-80. PubMed ID: 8252157
[TBL] [Abstract][Full Text] [Related]
15. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
16. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
[TBL] [Abstract][Full Text] [Related]
17. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
Huang JH; Hsu RB
Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
[TBL] [Abstract][Full Text] [Related]
19. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
20. Probable vancomycin-induced neutropenia.
Segarra-Newnham M; Tagoff SS
Ann Pharmacother; 2004 Nov; 38(11):1855-9. PubMed ID: 15466904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
